Asfrenon Mechanism of Action

Pharmacology: The pharmacological actions of this agent include Alpha-adrenergic stimulation (vasoconstrictions, nasal decongestion, pressor effects) B1 adrenergic stimulation (increased myocardial contractility and contraction). B2-adrenergic myocardial (bronchial dilation and vasodilation). Beta-adrenergic drugs stimulate adenylylcyclase, the enzymes that catalyze the formation of cyclic-3'5 adenosine monophosphate (cyclicAMP) from adenosine triphosphate (ATP). The cyclic AMP formed mediates the cellular responses.
In addition to the cardiovascular/pulmonary effects, other adrenergic actions include alpha receptor-mediated contraction GI and urinary sphincters. B1 receptor-mediated lipolysis, and B2 receptor-mediated decrease in GI tone, and increase in renin secretion, uterine relaxation, hepatic glycogenolysis/gluconeogenesis and pancreatic beta cell secretion.
The relative selectivity of actions of sympathomimetic agents is the primary determinant of clinical usefulness, it can predict the most likely side effects. The B2 selective agents provide the greatest benefit with minimal side effects. Direct administration via inhalation provides prompt and minimizes systematic activity. This drug inhibits histamine release from the mast cells, produce vasodilatation and increase ciliary motility.
Pharmacodynamics: Mechanism of Action: Salbutamol is used to produce bronchodilator or relieves nasal congestion. It relieves reversible bronchospasm by relaxing the smooth muscles of the bronchioles in conditions associated with asthma, bronchitis, emphysema or bronchiectasis. Bronchodilations may additionally facilitate expectoration.